FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171431378> ?p ?o ?g. }

• W3171431378 abstract "Abstract Background and Aims Autosomal dominant polycystic kidney disease (ADPKD) is a cause of progressive chronic kidney failure (CKD) and end stage kidney disease (ESKD). Tolvaptan has been shown within clinical trials to slow down decline of kidney function in patients with ADPKD at risk of rapid progression. We performed a retrospective review of a cohort of ADPKD patients who had been established on tolvaptan therapy to determine its efficacy in a real- world clinic setting. Method Subjects who had a clinical diagnosis of ADPKD and who had been established on tolvaptan for a period of &gt;18 months were reviewed retrospectively in terms of their eGFR. Subjects were between the ages of 18-65 years old and both males and females were included in this study. Other inclusion criteria involved a pre-treatment slope of &lt;-2.5 ml/min/1.73m2 based on readings for a 3 year period, a pre-treatment eGFR of 30-90 ml/min/1.73m2 and ability to tolerate tolvaptan treatment and be maintained on treatment for at least12 months. We calculated based on eGFR slopes, predicted time to reach CKD stage 5 with and without tolvaptan therapy. Given this was a retrospective review, eGFR were estimated during clinic visits whilst on tolvaptan treatment, rather than after a drug washout period. Results The cohort of patients included 20 from Newcastle upon Tyne Hospitals and 2 from Sunderland Royal Infirmary. The mean rate of eGFR decline prior to treatment was -5.92 ml/min/1.73m2 per year for the cohort. Following tolvaptan treatment, the average decline in eGFR was reduced to -2.57 ml/min/1.73m2 per year. Therefore, tolvaptan lessened average eGFR decline within this cohort by 3.35 ml/min/1.73m2 per year, gaining 7 years and 9 months delay until CKD stage 5. The majority of patients (n=19) received full dose tolvaptan (90mg/30mg). At an individual level, 3 patients failed to respond at all to tolvaptan, with no improvement in decline of GFR and 2 others had a very mild improvement only (change in eGFR slope of &lt;0.5 ml/min/1.73m2 per year). 6 patients had a dramatic improvement in eGFR slope (&gt;5 ml/min/1.73m2 per year). Conclusion The real life use of tolvaptan seemed to give a dramatic improvement in eGFR slopes, much more than the previously reported clinical studies have shown. This may be in part due to patient selection and only including patients who tolerated therapy, a “tolvaptan clinic” effect where great personal care is given to these patients and to excellent compliance with medication. Reasons for both non-response and exaggerated response need to be evaluated carefully to determine how individualisation of tolvaptan therapy can be best used." @default.
• W3171431378 created "2021-06-22" @default.
• W3171431378 creator A5026964990 @default.
• W3171431378 creator A5039376671 @default.
• W3171431378 creator A5040517393 @default.
• W3171431378 creator A5044826690 @default.
• W3171431378 creator A5060714825 @default.
• W3171431378 creator A5075356941 @default.
• W3171431378 creator A5080301968 @default.
• W3171431378 date "2021-05-01" @default.
• W3171431378 modified "2023-10-16" @default.
• W3171431378 title "MO040REAL-WORLD USE OF TOLVAPTAN AND ITS IMPACT ON EGFR IN A NORTH EAST UK COHORT" @default.
• W3171431378 doi "https://doi.org/10.1093/ndt/gfab080.0012" @default.
• W3171431378 hasPublicationYear "2021" @default.
• W3171431378 type Work @default.
• W3171431378 sameAs 3171431378 @default.
• W3171431378 citedByCount "0" @default.
• W3171431378 crossrefType "journal-article" @default.
• W3171431378 hasAuthorship W3171431378A5026964990 @default.
• W3171431378 hasAuthorship W3171431378A5039376671 @default.
• W3171431378 hasAuthorship W3171431378A5040517393 @default.
• W3171431378 hasAuthorship W3171431378A5044826690 @default.
• W3171431378 hasAuthorship W3171431378A5060714825 @default.
• W3171431378 hasAuthorship W3171431378A5075356941 @default.
• W3171431378 hasAuthorship W3171431378A5080301968 @default.
• W3171431378 hasConcept C126322002 @default.
• W3171431378 hasConcept C126894567 @default.
• W3171431378 hasConcept C159641895 @default.
• W3171431378 hasConcept C167135981 @default.
• W3171431378 hasConcept C2776266639 @default.
• W3171431378 hasConcept C2778198053 @default.
• W3171431378 hasConcept C2778653478 @default.
• W3171431378 hasConcept C2779134260 @default.
• W3171431378 hasConcept C2780615674 @default.
• W3171431378 hasConcept C71924100 @default.
• W3171431378 hasConcept C72563966 @default.
• W3171431378 hasConceptScore W3171431378C126322002 @default.
• W3171431378 hasConceptScore W3171431378C126894567 @default.
• W3171431378 hasConceptScore W3171431378C159641895 @default.
• W3171431378 hasConceptScore W3171431378C167135981 @default.
• W3171431378 hasConceptScore W3171431378C2776266639 @default.
• W3171431378 hasConceptScore W3171431378C2778198053 @default.
• W3171431378 hasConceptScore W3171431378C2778653478 @default.
• W3171431378 hasConceptScore W3171431378C2779134260 @default.
• W3171431378 hasConceptScore W3171431378C2780615674 @default.
• W3171431378 hasConceptScore W3171431378C71924100 @default.
• W3171431378 hasConceptScore W3171431378C72563966 @default.
• W3171431378 hasLocation W31714313781 @default.
• W3171431378 hasOpenAccess W3171431378 @default.
• W3171431378 hasPrimaryLocation W31714313781 @default.
• W3171431378 hasRelatedWork W10586329 @default.
• W3171431378 hasRelatedWork W11633418 @default.
• W3171431378 hasRelatedWork W13932552 @default.
• W3171431378 hasRelatedWork W14660073 @default.
• W3171431378 hasRelatedWork W15084687 @default.
• W3171431378 hasRelatedWork W19502387 @default.
• W3171431378 hasRelatedWork W20708886 @default.
• W3171431378 hasRelatedWork W5832825 @default.
• W3171431378 hasRelatedWork W6986156 @default.
• W3171431378 hasRelatedWork W1651283 @default.
• W3171431378 isParatext "false" @default.
• W3171431378 isRetracted "false" @default.
• W3171431378 magId "3171431378" @default.
• W3171431378 workType "article" @default.